Biolon®, first introduced in 1993, is an injectable system containing 1% fermentation-derived sodium hyaluronate (NaHA) used as a viscoelastic aid in cataract and other ophthalmic surgery. 


NaHA is a naturally occurring polysaccharide, ubiquitous in nature and chemically identical in all species. It is found in the vitreous and aqueous humor of the eye, in the synovial fluid surrounding knee and other joints, in skin and in other organs. This high molecular weight, ultra-pure sodium hyaluronate, is manufactured in Bio-Technology General’s Be'er Tuvia facility using an efficient biosynthetic process. It is used to lubricate the eye and maintain low intraocular pressure while facilitating surgery to reduce trauma to the corneal endothelium.

Biolon is approved in 30 countries and marketed in Israel, the United States, Europe and in other countries. BTG also produces a companion product, under the trade name Biolon Prime®, which contains 1.2% sodium hyaluronate.


Please note that product information presented on this website is intended only as a brief summary for the visitor's convenience in relation to the activities of the Ferring Group. Not all products or indications are licensed in every country and may be subject to further local variations. For advice on medical issues please consult your local medical practitioner.